Compare Stocks: IPHA, ANNX, RIGL, and CLYM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.01 +1.6%	$5.26	$2.32 ▼ $7.18	$761.16M	1.21	2.91 million shs	867,024 shs
CLYM Climb Bio	$14.86 +4.3%	$14.24	$1.54 ▼ $18.33	$855.40M	0.09	998,978 shs	241,206 shs
IPHA Innate Pharma	$1.84 -1.4%	$1.97	$1.17 ▼ $2.71	$206.01M	0.34	83,711 shs	8,252 shs
RIGL Rigel Pharmaceuticals	$45.69 -3.3%	$42.74	$24.95 ▼ $52.24	$845.27M	1.2	362,980 shs	87,462 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-19.10%	-25.52%	-15.09%	+62.81%
CLYM Climb Bio	0.00%	-8.18%	-12.74%	+24.02%	+533.33%
IPHA Innate Pharma	0.00%	-10.10%	-14.22%	+4.47%	-6.50%
RIGL Rigel Pharmaceuticals	0.00%	-2.94%	+10.94%	+41.35%	+24.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.01 +1.6%	$5.26	$2.32 ▼ $7.18	$761.16M	1.21	2.91 million shs	867,024 shs
CLYM Climb Bio	$14.86 +4.3%	$14.24	$1.54 ▼ $18.33	$855.40M	0.09	998,978 shs	241,206 shs
IPHA Innate Pharma	$1.84 -1.4%	$1.97	$1.17 ▼ $2.71	$206.01M	0.34	83,711 shs	8,252 shs
RIGL Rigel Pharmaceuticals	$45.69 -3.3%	$42.74	$24.95 ▼ $52.24	$845.27M	1.2	362,980 shs	87,462 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-19.10%	-25.52%	-15.09%	+62.81%
CLYM Climb Bio	0.00%	-8.18%	-12.74%	+24.02%	+533.33%
IPHA Innate Pharma	0.00%	-10.10%	-14.22%	+4.47%	-6.50%
RIGL Rigel Pharmaceuticals	0.00%	-2.94%	+10.94%	+41.35%	+24.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	278.10% Upside
CLYM Climb Bio	3.00	Buy	$26.92	81.18% Upside
IPHA Innate Pharma	2.67	Moderate Buy	$6.67	261.53% Upside
RIGL Rigel Pharmaceuticals	2.57	Moderate Buy	$59.00	29.13% Upside

Current Analyst Ratings Breakdown

Latest IPHA, ANNX, RIGL, and CLYM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/8/2026	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$18.00 ➝ $25.00
9/8/2026	CLYM Climb Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $30.00
9/7/2026	CLYM Climb Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/4/2026	CLYM Climb Bio	B Riley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/4/2026	CLYM Climb Bio	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00 ➝ $30.00
9/3/2026	CLYM Climb Bio	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$40.00
9/3/2026	CLYM Climb Bio	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$21.00 ➝ $25.00
9/3/2026	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $32.00
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.36 per share	N/A
IPHA Innate Pharma	$10.19M	20.22	N/A	N/A	($0.26) per share	-7.09
RIGL Rigel Pharmaceuticals	$294.28M	2.87	$6.52 per share	7.01	$21.57 per share	2.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
CLYM Climb Bio	-$59.85M	-$0.83	N/A	N/A	N/A	N/A	-31.79%	-30.79%	11/11/2026 (Estimated)
IPHA Innate Pharma	-$55.64M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/17/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.80	10.58	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)

Latest IPHA, ANNX, RIGL, and CLYM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/17/2026	Q2 2026	IPHA Innate Pharma	-$0.2946	N/A	N/A	N/A	$6.35 million	N/A
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	CLYM Climb Bio	-$0.2093	-$0.18	+$0.0293	-$0.18	N/A	N/A
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
CLYM Climb Bio	N/A	31.45	31.45
IPHA Innate Pharma	N/A	1.27	1.27
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CLYM Climb Bio	69.76%
IPHA Innate Pharma	0.16%
RIGL Rigel Pharmaceuticals	66.23%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
CLYM Climb Bio	2.60%
IPHA Innate Pharma	31.89%
RIGL Rigel Pharmaceuticals	10.47%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
CLYM Climb Bio	29	57.44 million	55.94 million	N/A
IPHA Innate Pharma	220	111.72 million	76.09 million	Not Optionable
RIGL Rigel Pharmaceuticals	174	18.50 million	16.57 million	Optionable

IPHA, ANNX, RIGL, and CLYM Headlines

Recent News About These Companies

Squarepoint Ops LLC Acquires 38,550 Shares of Rigel Pharmaceuticals, Inc. $RIGL

September 14 at 4:16 AM | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) and Aclaris Therapeutics (NASDAQ:ACRS) Critical Contrast

September 11 at 2:14 AM | americanbankingnews.com

Bank of New York Mellon Corp Purchases Shares of 108,209 Rigel Pharmaceuticals, Inc. $RIGL

September 6, 2026 | marketbeat.com

Man Group plc Invests $814,000 in Rigel Pharmaceuticals, Inc. $RIGL

September 4, 2026 | marketbeat.com

Rigel to Participate in Upcoming September Investor Conferences

September 2, 2026 | prnewswire.com

Jupiter Topco LLC Invests $3.45 Million in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

Empowered Funds LLC Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

September 2, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Rigel Pharmaceuticals, Inc. $RIGL

August 31, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Buys Shares of 49,096 Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

Bank of America Corp DE Has $3.90 Million Stock Holdings in Rigel Pharmaceuticals, Inc. $RIGL

August 30, 2026 | marketbeat.com

OMERS ADMINISTRATION Corp Invests $2.03 Million in Rigel Pharmaceuticals, Inc. $RIGL

August 27, 2026 | marketbeat.com

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by Brokerages

August 26, 2026 | marketbeat.com

Globeflex Capital L P Takes Position in Rigel Pharmaceuticals, Inc. $RIGL

August 24, 2026 | marketbeat.com

Rigel Pharmaceuticals (NASDAQ:RIGL) Rating Increased to Hold at Zacks Research

August 19, 2026 | marketbeat.com

HC Wainwright Analysts Increase Earnings Estimates for RIGL

August 18, 2026 | marketbeat.com

Rigel Pharmaceuticals

August 17, 2026 | money.usnews.com

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

August 13, 2026 | prnewswire.com

Rigel Pharmaceuticals en quête d'acquisitions

August 5, 2026 | zonebourse.comZ

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

August 5, 2026 | seekingalpha.com

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

August 5, 2026 | seekingalpha.com

Rigel: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ANNX, RIGL, and CLYM Company Descriptions

Annexon NASDAQ:ANNX

$4.00 +0.07 (+1.65%)

As of 11:48 AM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Climb Bio NASDAQ:CLYM

$14.86 +0.61 (+4.28%)

As of 11:48 AM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Innate Pharma NASDAQ:IPHA

$1.84 -0.03 (-1.39%)

As of 11:41 AM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Rigel Pharmaceuticals NASDAQ:RIGL

$45.69 -1.55 (-3.28%)

As of 11:48 AM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, ANNX, RIGL, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, ANNX, RIGL, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, ANNX, RIGL, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ANNX, RIGL, and CLYM Company Descriptions

Annexon NASDAQ:ANNX

Climb Bio NASDAQ:CLYM

Innate Pharma NASDAQ:IPHA

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IPHA, ANNX, RIGL, and CLYM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IPHA, ANNX, RIGL, and CLYM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IPHA, ANNX, RIGL, and CLYM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA, ANNX, RIGL, and CLYM Company Descriptions

Annexon NASDAQ:ANNX

Climb Bio NASDAQ:CLYM

Innate Pharma NASDAQ:IPHA

Rigel Pharmaceuticals NASDAQ:RIGL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools